EP1283262A1 - Agent induisant l'expression du facteur neurotrophique - Google Patents

Agent induisant l'expression du facteur neurotrophique Download PDF

Info

Publication number
EP1283262A1
EP1283262A1 EP01917711A EP01917711A EP1283262A1 EP 1283262 A1 EP1283262 A1 EP 1283262A1 EP 01917711 A EP01917711 A EP 01917711A EP 01917711 A EP01917711 A EP 01917711A EP 1283262 A1 EP1283262 A1 EP 1283262A1
Authority
EP
European Patent Office
Prior art keywords
psec56
protein
expression
neurotrophic factor
ngf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01917711A
Other languages
German (de)
English (en)
Other versions
EP1283262A4 (fr
Inventor
Cristina Mitsumori
Noriyuki Morikawa
Koji Hayashi
Kenji Nagahari
Toshio Ota
Yuri Hio
Tetsuo Nishikawa
Takao Isogai
Masakazu c/o Mitsubishi Pharma Corp. KAWASAKI
Kenji c/o Mitsubishi Pharma Corpor. HASHIMOTO
Toshimitsu c/o Mitsubishi Pharma Corp. KISHIMOTO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Helix Research Institute
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Research Institute, Mitsubishi Pharma Corp filed Critical Helix Research Institute
Publication of EP1283262A1 publication Critical patent/EP1283262A1/fr
Publication of EP1283262A4 publication Critical patent/EP1283262A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • the present invention relates to neurotrophic factor expression-inducing agents, a method for inducing the expression of neurotrophic factors, and a method of screening for compounds that regulate the induction of neurotrophic factor expression.
  • Neurotrophic factor is a factor that has the activity to maintain the survival and function of neurons, and promoting neurites extension.
  • NTF Neurotrophic factor
  • neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), NT-3, and NT-4/5
  • NGF, BDNF, NT-3, and NT-4/5 share a very similar physical and chemical structure with a similar physiological function, and are generically called neurotrophins.
  • various cytokines such as ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), glial cell line-derived neurotrophic factor (GDNF), insulin-like growth factor-I and -II (IGF-I and -II, respectively) , and interleukin-6 (IL-6) have been isolated.
  • CNTF ciliary neurotrophic factor
  • bFGF basic fibroblast growth factor
  • EGF epidermal growth factor
  • GDNF glial cell line-derived neurotrophic factor
  • IGF-I and -II insulin-like growth factor-I and -II, respectively
  • IL-6 interle
  • neurotrophic factors are widely tried to treat diseases accompanying neuronal degeneration and neuronal cell death, regardless of whether they belong to the central or peripheral nervous system. Furthermore, recently, although it is in the preclinical stages, gene therapy by neurotrophic factors is being planned. Moreover, use of neurotrophic factors for elevating the adhesion rate during transplantation of fetal neuron to the brain is also considered.
  • NGF nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • NT-3 ciliary neurotrophic factor
  • CNTF ciliary neurotrophic factor
  • a neurotrophic factor itself, but also factors that induce the expression of a neurotrophic factor.
  • the production mechanism of neurotrophic factors and several compounds that promote the production of the factors are known.
  • a ⁇ 2,3 agonist, clenbuterol is known to promote NGF expression in glial cells via a ⁇ -adrenaline receptor.
  • Increase of cyclic-adenosine monophosphate (cAMP) followed by the activation of cAMP-activated protein kinase (PKA) is reported to be involved in the pathway after adrenaline receptor stimulation.
  • cAMP cyclic-adenosine monophosphate
  • PKA cAMP-activated protein kinase
  • ⁇ -adrenaline receptor The activation of PKA via the ⁇ -adrenaline receptor is only an example of the pathways of NGF expression, and other molecular mechanisms involving various chemical substance and test systems that regulate the expression of neurotrophic factors, such as NGF, have been reported. Such mechanisms include pathways such as those involving PKA activation and cAMP increase by forskolin; those involving calcium-dependent protein kinase (PKC) activation by diacylglycerol and phorbol ester; and those via sphingomyelin involving vitamin D3, interleukin-1 ⁇ (IL-1 ⁇ ), lipopolysaccharide, and ceramide (Semkova, I. and Krieglstein, J. (1999) Brain Res. Rev. 30, 176-188).
  • aFGF is known to induce NGF production from glial cells (Neuroscience Letters 126, 18-20 (1991)).
  • IL-1 and catecholamine are also known to induce the expression of NGF.
  • Xaliproden (SR-57746) is an example of neurotrophic factor expression-inducing agent that is being developed as a medicament. This substance is basically a 5-HT1A receptor agonist, and is reported to enhance NGF production via an unknown action mechanism to improve neuropathy in animal models. Clinical tests of Xaliproden for amyotropic lateral sclerosis and Alzheimer's disease are in progress. Application thereof to gene therapy by neurotrophic factors are also being considered.
  • neurotrophic factors themselves and agents inducing them.
  • inducing agents if they are small molecules that go through the blood brain barrier, are expected to show effects on diseases of the central nervous system.
  • constitutive expression of neurotrophic factors can be expected gene therapy and/or administration of inducing agents.
  • the inducing agents are small molecules, simplified (oral, subcutaneous, and such) administration enables maintenance of a necessary concentration in vivo , and as a consequence, constitutive expression of the neurotrophic factors can be expected.
  • This present invention has been made in view of such situation, and its objective is to identify factors that induce the expression of neurotrophic factors to provide neurotrophic factor expression-inducing agents, method for inducing the expression of neurotrophic factors, and method of screening for compounds that regulate the induction of neurotrophic factor expression that utilize these identified factors.
  • the present inventors treated NT-2 nerve progenitor cells, human fetal testis-derived teratocarcinoma cells, with retinoic acid, prepared mRNAs from the treated cells, and then cloned a plurality of full-length cDNAs from the mRNAs by the oligo-capping method.
  • the nucleotide sequences of these full-length cDNAs were analyzed, and a novel gene (PSEC56) with a secretory signal was discovered among them.
  • the inventors transfected the gene into COS cells, and examined the activity of the culture supernatant of COS cells expressing the gene on dorsal root ganglion (DRG) cells . As a result, this culture supernatant was revealed to have a neurite extension effect towards these cells. On the other hand, PSEC56 protein itself purified by metal affinity column from the culture supernatant did not show any neurite extension effect on DRG cells.
  • DRG dorsal root ganglion
  • the present inventors performed analyses to identify the main substance of the activity included in this culture supernatant.
  • the neurite extension effect of the culture supernatant on DRG cells was suppressed by treating the culture supernatant of PSEC56 transfected COS-7 cells with antibodies against NGF.
  • NGF was detected in the culture supernatant of COS-7 cells transfected with the PSEC56 gene. That is, the present inventors demonstrated NGF as the main substance of activity within the culture supernatant.
  • the PSEC56 protein and genes encoding said protein can be utilized as inducing agents of NGF expression in cells. Furthermore, the inducing system of NGF expression by PSEC56 protein expression may be also utilized for the development of therapeutic agents and preventive agents for diseases of the nervous system.
  • This invention is based on the above findings and specifically provides:
  • This invention provides neurotrophic factor expression-inducing agents, wherein PSEC56 protein or DNA encoding the protein serves as an active ingredient.
  • PSEC56 protein includes the PSEC56 protein of SEQ ID NO: 2, as well as proteins functionally equivalent thereto.
  • proteins functionally equivalent to PSEC56 protein of SEQ ID NO: 2 refers to proteins that are highly homologous, at the primary structure, to the PSEC56 protein of SEQ ID NO: 2 at the primary structure, and which, similarly to the PSEC56 protein of SEQ ID NO: 2, have the activity to induce neurotrophic factor expression upon their expression. It may be any protein with any kind of name.
  • the term "highly homologous” refers to a sequence identity of at least 40% or more, preferably 60% or more, and more preferably 80% or more (for example, 90% or more, or 95% or more).
  • examples of such proteins are mutants and variants of the PSEC56 protein of SEQ ID NO: 2, and homologous proteins derived from other organisms, but are not limited to these examples .
  • the activity of a test protein to induce neurotrophic factors can be detected, for example, by expressing the test protein in COS cells, and detecting, as an indicator, secretion of neurotrophic factors, such as NGF, into the culture supernatant (see Example 2).
  • a protein that is functionally equivalent to the PSEC56 protein of SEQ ID NO: 2 can be prepared by one skilled in the art by, for example, a method for introducing mutations to the amino acid sequence of a protein (for example, site-directed mutagenesis (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 8.1-8.5)). Such proteins may also be produced by naturally occurring amino acid mutations.
  • the "PSEC56 protein” of this invention includes proteins that are functionally equivalent to the PSEC56 protein of SEQ ID NO: 2, in which one or more amino acids of the PSEC56 protein of SEQ ID NO: 2 have been substituted, deleted, inserted, and/or added.
  • the number of mutations and the sites of mutation of amino acids in the protein there are no limitations on the number of mutations and the sites of mutation of amino acids in the protein as long as its function is maintained. Typically, the number of mutations is 10% or less of all amino acids, preferably 5% or less of all amino acids, and more preferably 1% or less of all amino acids.
  • Proteins with deletion of amino acids from the PSEC56 protein include, for example, proteins in which a signal peptide has been removed.
  • a protein that is functionally equivalent to the PSEC56 protein of SEQ ID NO: 2 can be isolated using hybridization techniques or gene amplification techniques well known to those skilled in the art. That is, one skilled in the art can ordinarily isolate a DNA highly homologous to a probe from biological samples including human, rat, mouse, and such; and then, prepare the corresponding protein from the isolated DNA utilizing hybridization techniques wherein the DNA (SEQ ID NO: 1) encoding the PSEC56 protein of SEQ ID NO: 2 or parts thereof is used as a probe (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 6.3-6.4).
  • a stringent hybridization condition for isolating DNAs encoding such proteins is usually "1x SSC, 0.1% SDS, 37°C” or so, a more stringent condition “0.5x SSC, 0.1% SDS, 42°C” or so, and an even more stringent condition “0.2x SSC, 0.1% SDS, 65°C” or so.
  • the more stringent the condition for hybridization the more efficient isolation of a DNA with a higher homology with the probe sequence is expected.
  • PCR gene amplification techniques
  • SEQ ID NO: 1 DNA sequence encoding the PSEC56 protein of SEQ ID NO: 2 or parts thereof by designing primers based on the information of the DNA sequence encoding the PSEC56 protein.
  • proteins that are functionally equivalent to the PSEC56 protein of SEQ ID NO: 2 can be obtained.
  • Proteins encoded by the DNAs that are isolated using such hybridization techniques and gene amplification techniques usually have high sequence homology at the amino acid sequence level to the PSEC56 protein of SEQ ID NO: 2.
  • a nucleotide sequence is determined as "homologous" by performing a sequence homology search with BLAST N, for example, when the sequence shows a homology of 40% or higher to a region of 400 bp or longer of the 1746 bp DNA region encoding the PSEC56 protein.
  • an amino acid sequence can be determined "homologous” by performing a sequence homology search with BLAST X, for example, when the sequence indicates a homology of 30% or higher to a region of 80 residues or longer of the 582 residue of the PSEC56 protein.
  • sequence homologies can be determined using other search algorithms, such as FASTA and Smith-Waterman (GenBank (http://www.ncbi.nlm.nih.gov/web/GenBank/)).
  • the PSEC56 sequence shows sequence homologies of 49%, 48%, and 48% at 185 bp- 751 bp, 552 bp- 986 bp, and 1213 bp- 1635 bp, respectively, to human FKBP12.
  • the PSEC56 has a primary structure wherein three FKBP domains are aligned.
  • a "His-Glu-Glu-Leu" sequence which is predicted to be an endoplasmic reticulum translocation signal, has been confirmed.
  • the PSEC56 sequence has 76% sequence homology (1-2632 bp), and 88% amino acid homology (1-582 residues) with mouse FKBP65.
  • the active ingredient of the expression-inducing agent of the present invention include proteins that are functionally equivalent to the PSEC56 protein of SEQ ID NO: 2, which proteins are encoded by DNAs that hybridize with a DNA encoding the PSEC56 protein of SEQ ID NO: 2.
  • the PSEC56 protein can be prepared as a recombinant protein, or as a naturally occurring protein.
  • the recombinant protein can be prepared, for example, by introducing a vector to which a DNA encoding the PSEC56 protein has been inserted to an appropriate host cell, and then purifying the proteins expressed in the transfectant or those secreted into the culture supernatant.
  • the naturally occurring protein can be prepared, for example, using an affinity column bound to antibodies against the PSEC56 protein (Current Protocols in Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley & Sons Section 16.1-16.19).
  • DNA encoding the PSEC56 protein which is an active ingredient of the expression-inducing agent of this invention, and includes cDNAs, as well as genomic DNAs, chemically synthesized DNAs, etc.
  • the DNAs of this invention can be prepared by standard methods, such as hybridization methods using a DNA sequence (for example, SEQ ID NO: 1) encoding the PSEC56 protein or parts thereof as a probe, or PCR methods using primers synthesized based on the DNA sequence information.
  • the DNA is inserted into a vector that ensures its intracellular expression.
  • vectors include pME18S FL3, pcDNA3.1(-), pcDNA3.1(+), etc.
  • the expression-inducing agent of this invention may be used as a reagent for experimental research.
  • the agent can be used as a medicament for treatment or prevention of diseases, such as diseases of the nervous system. That is, the "expression-inducing agent" of this invention includes both reagents and medicaments.
  • neurotrophic factors to be induced by the expression-inducing agent of this invention are BDNF, NT-3, NT-4/5, CNTF, GDNF besides NGF, but are not limited to these examples.
  • neurotrophic factors herein refer to cell growth factors that act on cerebral nervous system and especially those having growth, differentiation, and (survival and/or functional) maintenance effects on neurons.
  • the present invention also provides a method to induce the expression of neurotrophic factors.
  • This method includes the step of expressing the PSEC56 protein.
  • cells that are applicable for this method, and various cells are used according to the objective. For example, glial cells and Schwann cells that produce neurotrophic factors may be mainly used; but the present invention is not limited to these examples.
  • a DNA encoding the PSEC56 protein is inserted into a vector that ensures intracellular expression, and the vector is transfected into a target cell.
  • Examples of conventional methods for the transfection of a vector into a cell includes the lipofectamine method, the calcium phosphate precipitation method, the electroporation method, the microinjection method, etc., but are not limited to these examples.
  • vectors derived from viruses such as retrovirus, adenovirus, and Sendai virus; and non-viral vectors such as liposomes may be used. In such cases, besides in vivo administration, ex vivo administration may also be conducted.
  • the present invention provides a method of screening for compounds that regulate the induction of neutrophic factor expression caused by the PSEC56 protein.
  • the screening method of this invention is characterized by the steps of adding a test sample to the above-mentioned expression induction system of neurotrophic factors, and then evaluating the effect of the test sample on the neurotrophic factor expression in response to PSEC56 expression. More specifically, the screening method of this invention can be carried out by the steps of: (a) contacting a test sample with a transfected cell that includes an expressive DNA encoding the PSEC56 protein; (b) detecting neurotrophic factor expression in the cell; and (c) selecting the compound that enhances or suppresses the induction of neurotrophic factor expression compared to the expression detected in the absence of the test sample.
  • Transfected cells used for the screening can be prepared by transfecting a cell with a vector to which a DNA encoding the PSEC56 protein has been inserted by the above-mentioned well-known methods for gene transfection.
  • a vector to which a DNA encoding the PSEC56 protein has been inserted.
  • the host cell to be transfected with a vector There are no particular limitations on the host cell to be transfected with a vector.
  • Various cells are used according to the objective, and for example, COS cells and CHO cells are preferably used as eukaryotic cells for enhanced expression of the protein of interest.
  • in vivo cells are exemplified by glial cells and Schwann cells that produce neurotrophic factors, but are not limited thereto.
  • test samples that are contacted with the cells prepared in this manner.
  • cell extracts, expression products of gene libraries, synthetic low molecular weight compounds, synthetic polypeptides, and naturally occurring compounds may be used, but is not limited to these examples.
  • the expression of a neurotrophic factor is detected after the contact of cells with a test sample.
  • the expression of neurotrophic factors can be detected by performing Western Blotting using antibodies against the neurotrophic factors on the culture supernatant of transfected cells with the PSEC56 gene.
  • the used test sample is determined to promote the induction of the expression of the neurotrophic factor; and on the contrary, if the expression level of the neurotrophic factor is diminished compared to the control, the used test sample is determined to suppress the induction of the neurotrophic factor expression.
  • PSEC56 protein and genes encoding the protein, as well as compounds isolated by the screening method of the present invention are expected to be applicable as therapeutic drugs and/or preventive drugs for spinal injury and diseases of the peripheral nerves, as well as diseases of the central nerve system including dementia, cerebral infarction, etc.
  • virus vectors such as retrovirus vector and adenovirus vector, or non-virus vectors such as liposomes, are used for administration to patients.
  • administration methods include in vivo methods and ex vivo methods.
  • PSEC56 protein and compounds isolated by the screening method of the present invention when using the PSEC56 protein and compounds isolated by the screening method of the present invention as medicaments, besides directly administering them to patients, they can be administered upon formulation by conventional preparation methods.
  • they can be administered orally or parenterally in forms such as tablets, capsules, granules, injections, and drops that are obtained via a normal preparation of medicinal components by mixing with pharmaceutical acceptable carriers (fillers, binders, disintegrators, corrigents, flavors, emulsifiers, and such), diluents, solubilizers, etc.
  • Tablets for oral administration include normally used carriers, such as sucrose, lactose, mannitol, maltitol, dextran, corn starch, and such; and typically include lubricants, such as magnesium stearate; preservatives, such as parabens and sorbic acids; antioxidants, such as ascorbic acid, ⁇ -tocopherol, and cysteine; disintegrators; binders; etc. Lactose and dried corn starch are effective diluents for capsule for oral administration.
  • Ordinary parenteral administrations such as intravenous injections, intraperitoneal injections, and infusions, are prepared by appropriately adjusting the pH of the active ingredient solution, and then buffering and sterilizing the solution.
  • vehicles and solvents include distilled water, Ringer solution, isotonic saline solution, etc.
  • the total concentration of solute should be adjusted to make the solution isotonic.
  • the dose for administration is determined by taking the age, weight, administration time, method of administration, combination of drugs, and the condition of the disease of a patient to be treated, and other factors into consideration.
  • the daily dose differs depending on the condition and weight of the patient, type of compound, administration route, and such, but for example, approximately 0.01 mg/patient/day to 1000 mg/patient/day, preferably 0.1 mg/patient/day to 300 mg/patient/day is preferred for oral administration; and approximately a dose of 0.01 mg/patient/day to 50 mg/patient/day, preferably 0.01 mg/patient/day to 10 mg/patient/day is preferably administered subcutaneously or intravenously for parenteral administration.
  • NT-2 nerve progenitor cells purchased from Stratagene
  • NT-2 nerve progenitor cells which are human fetal testis-derived teratocarcinoma cells that can be differentiate into neurons by a treatment with retinoic acid
  • NT-2 cells were cultivated, retinoic acid was added thereto, and the mixture was cultivated for another 2 weeks.
  • These cultivated cells were collected to extract mRNAs according to the literature (J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular Cloning Second edition, Cold Spring Harbor Laboratory Press, 1989).
  • polyA(+)RNA was purified using oligo dT cellulose.
  • cDNA was cloned from polyA(+)RNA by the oligo-capping method (M. Maruyama and S. Sugano, Gene, 138, 171-174 (1994)).
  • oligo-cap linker SEQ ID NO: 4
  • oligo dT primer SEQ ID NO: 5
  • BAP Bacterial Alkaline Phosphatase
  • TAP tobacco Acid Phosphatase
  • a DNA sequencing reagent (Dye Terminator Cycle Sequencing FS Ready Reaction Kit, PE Applied Biosystems) following the instructions, the nucleotide sequence of the DNA was analyzed using a DNA sequencer (ABI PRISM 377, PE Applied Biosystems). The longest possible nucleotide sequence from the 5' end of each clone was determined by one pass sequencing. Then, cDNA clone PSEC56 was selected as a clone having a signal sequence by PSORT (Proc. Fourth Int. Conf. Intell. Sys. Mol. Biol., p.
  • nucleotide sequence of PSEC56 The nucleotide sequence of PSEC56, the amino acid sequence of the ORF predicted from the nucleotide sequence of PSEC56, and the predicted signal sequence of PSEC56 are shown in SEQ ID NOs: 1, 2, and 3, respectively.
  • DRG dorsal root ganglion
  • the neurocytes Upon removal of adherent cells other than neurocytes, the neurocytes were plated on a polylysine-coated 96-well plate (5,000 cells/well), and was cultivated for two days in D-MEM containing a test sample and 10% FCS in a CO 2 incubator. As a positive control, nerve growth factor (NGF) was used.
  • NGF nerve growth factor
  • Neurite extension of cells prepared by the above-mentioned method were measured by Cell-based ELISA using the expression of neurofilaments as an indicator of neurite extension. Specifically, cells were immobilized with formalin, were made highly permeable with a surfactant (Triton X-100), and were reacted with specific antibodies (SMI31; Sternberger) against neurofilaments. Next, the aforementioned antibodies were detected with peroxidase-labeled antibodies and peroxidase staining kit T (Sumitomo Bakelite) to measure the absorbance at 450 nm with a microplate reader.
  • NGF in the culture supernatant were detected by Enzyme-Linked ImmunoSorbent Assay (ELISA) according to the instructions attached to NGF measurement kit from Promega (NGF E max TM ImmunoAssay System) . More specifically, a 96-well micro test plate was coated with anti-NGF polyclonal antibodies. After blocking, test substances were added thereto, and antigen-antibody reaction was carried out. Following the antigen-antibody reaction by the addition of anti-NGF monoclonal antibodies, anti-rat IgG antibodies labeled with enzymes were added as secondary antibodies. Finally, a substrate, which forms colors through an enzyme reaction, was added thereto. NGF was quantified by measuring the absorbance of the color forming substrate.
  • ELISA Enzyme-Linked ImmunoSorbent Assay
  • NGF was detected from the culture supernatant (approximately 100 ng/mL). However, no NGF could be detected by the Mock transfection.
  • the DNA of PSEC56 was inserted into a vector for the addition of Myc and polyhistidine tag (pcDNA3.1(-)/MycHis-A; INVITROGEN).
  • the expression vector was introduced into COS-7 cells by the calcium phosphate method or by the lipofectamine method. 3 days later, the culture supernatant was collected.
  • the polyhistidine-attached PSEC56 protein was purified from this culture supernatant using a metal affinity column (HisTrap; Amersham Pharmacia). Specifically, the culture supernatant was passed through a HisTrap column to which nickel ion was added, and the Myc-His-PSEC56 protein bound to the column was eluted using a desired concentration of imidazole solution. Fractions containing the Myc-His-PSEC56 protein were confirmed by Western Blotting using SDS-PAGE and anti-Myc antibody (Fig. 5). Since imidazole was used for the elution from the column, after collecting the fractions of interest, they were desalted by gel filtration using a PD-10 column (Amersham Pharmacia) for later experiments.
  • the present invention provides neurotrophic factor expression-inducing agents, a method for inducing the expression of neurotrophic factors, and a method of screening for compounds that regulate the induction of neurotrophic factor expression utilizing PSEC56.
  • This invention enables elucidation of the mechanism leading to the induction and secretion of neurotrophic factors, such as NGF, by PSEC56; and development of novel therapeutic drugs and preventive drugs for diseases of the central nervous system, such as dementia and cerebral infarction, as well as spinal injury and diseases of the peripheral nerves.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01917711A 2000-03-31 2001-03-30 Agent induisant l'expression du facteur neurotrophique Withdrawn EP1283262A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000101300 2000-03-31
JP2000101300 2000-03-31
PCT/JP2001/002768 WO2001073024A1 (fr) 2000-03-31 2001-03-30 Agent induisant l'expression du facteur neurotrophique

Publications (2)

Publication Number Publication Date
EP1283262A1 true EP1283262A1 (fr) 2003-02-12
EP1283262A4 EP1283262A4 (fr) 2004-07-14

Family

ID=18615381

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01917711A Withdrawn EP1283262A4 (fr) 2000-03-31 2001-03-30 Agent induisant l'expression du facteur neurotrophique

Country Status (5)

Country Link
US (1) US20030186332A1 (fr)
EP (1) EP1283262A4 (fr)
JP (1) JP3836372B2 (fr)
AU (1) AU2001244674A1 (fr)
WO (1) WO2001073024A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849055A1 (fr) * 2002-12-18 2004-06-25 Exonhit Therapeutics Sa Nouvelle cible moleculaire de l'angiogenese et utilisations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057642A (ja) * 2009-09-14 2011-03-24 National Agriculture & Food Research Organization 神経突起伸展促進剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266753A1 (fr) * 1996-09-19 1998-03-26 Spinal Cord Society Procede d'integration stable d'adn dans des neurones
US5989860A (en) * 1997-12-12 1999-11-23 Incyte Pharmaceuticals, Inc. Human isomerase homologs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COSS M C ET AL: "MOLECULAR CLONING, DNA SEQUENCE ANALYSIS, AND BIOCHEMICAL CHARACTERIZATION OF A NOVEL 65-KDA FK506-BINDING PROTEIN (FKBP65)" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 49, 8 December 1995 (1995-12-08), pages 29336-29341, XP002917765 ISSN: 0021-9258 -& DATABASE EMBL [Online] retrieved from EBI Database accession no. L07063 XP002278995 *
DATABASE EMBL [Online] retrieved from EBI Database accession no. BAB20974 XP002278996 *
HAMILTON G S: "IMMUNOPHILIN LIGANDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 9, 1998, pages 1109-1124, XP000852684 ISSN: 1354-3776 *
See also references of WO0173024A1 *
SIMEK STEPHANIE L ET AL: "Sequence and localization of a novel FK506-binding protein to mouse chromosome 11" GENOMICS, vol. 18, no. 2, 1993, pages 407-409, XP002278994 ISSN: 0888-7543 *
SNYDER S H ET AL: "IMMUNOPHILINS IN THE NERVOUS SYSTEM" NEURON, CAMBRIDGE, MA, US, vol. 21, no. 2, 1998, pages 283-294, XP000878557 *
ZENG B ET AL: "CHICKEN FK506-BINDING PROTEIN, FKBP65, A MEMBER OF THE FKBP FAMILY OF PEPTIDYLPROPYL CIS-TRANS ISOMERASE, IS ONLY PARTIALLY INHIBITED BY FK506" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 330, no. 1, 15 February 1998 (1998-02-15), pages 109-114, XP001154046 ISSN: 0264-6021 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849055A1 (fr) * 2002-12-18 2004-06-25 Exonhit Therapeutics Sa Nouvelle cible moleculaire de l'angiogenese et utilisations

Also Published As

Publication number Publication date
US20030186332A1 (en) 2003-10-02
EP1283262A4 (fr) 2004-07-14
JP3836372B2 (ja) 2006-10-25
AU2001244674A1 (en) 2001-10-08
WO2001073024A1 (fr) 2001-10-04

Similar Documents

Publication Publication Date Title
KR100426453B1 (ko) 인간 자궁경부암 2 원암 유전자 및 이에 의해 코딩되는단백질, 이를 포함하는 발현벡터 및 이 벡터로 형질전환된세포
US11129879B2 (en) Methods for the treatment of neurological disorders and diseases using FNDC5
Heller et al. Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development
EP1283262A1 (fr) Agent induisant l'expression du facteur neurotrophique
US7273922B2 (en) Semaphorin Z and gene encoding the same
EP1701978B1 (fr) Utilisation de T-Cadhérine soluble pour le traitement de troubles métaboliques
US20020137095A1 (en) Reelin protein CR-50 epitope region
US7749758B2 (en) Human and mammalian stem cell-derived neuron survival factors
US6558912B1 (en) NRAGE nucleic acids and polypeptides and uses thereof
EP1613769B1 (fr) Gene induit par l'insuline utilise comme cible therapeutique dans le diabete
JP4000313B2 (ja) 医薬組成物
KR20080044205A (ko) 저산소 스트레스 응답에 관여하는 Int6 단백질, 및 그 용도
US20040266677A1 (en) Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof
EP1122312A1 (fr) Nouvelle proteine war-1 et son gene
JP5119510B2 (ja) 肥満の予防・治療剤
US20040102375A1 (en) Methods to overcome inhibition of growth cone translocation
EP1705256A1 (fr) Procédé de traitement de résistance à l'insuline et d'états pathologiques caractérisés par une résistance à l'insuline
WO2008066744A2 (fr) Procédés et compositions de traitement et de prévention des lésions de la moelle épinière et d'autres maladies ou lésions cérébrales
KR20220145254A (ko) Trex1의 유전성 강직성 하반신 마비의 치료 용도
US20030105287A1 (en) Inhibition of the proliferation of cells of the multiple myeloma
JP4952944B2 (ja) Ｓｉｎｇａｒの発現または機能の抑制による神経軸索の形成・伸長と神経再生への応用
WO2009030094A1 (fr) Fonction et utilisation d'une nouvelle protéine induisant une apoptose associée aux lysosomes contenant les domaines ph et fyve (lapf)
WO2000039315A1 (fr) Promoteur ucp-2 et son utilisation
JP2005263633A (ja) 新規神経栄養因子
JP2006166703A (ja) 軟骨分化制御遺伝子

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021022

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI PHARMA CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20040528

17Q First examination report despatched

Effective date: 20060706

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070117